Skip to content
type1.science

Verapamil (oral)

Generic (repurposed calcium-channel blocker)

A modest help, available off-label.

A cheap, long-established blood-pressure pill repurposed to help preserve the body's own insulin production when started near diagnosis of clinical (stage 3) T1D. A real but modest effect; used off-label, not yet a standard therapy, and its largest adult trial narrowly missed its main goal.

Available (off-label)Moderate evidencerepurposedbeta-cell-preservationoraloff-labelnew-onset

The scorecard

Delay of onset35

Doesn't delay clinical onset; it preserves residual insulin production after diagnosis — a different, modest benefit (~30% higher C-peptide at 1 year in children).[3]

Durability45

Benefit lasts at least two years while taken, but is lost on stopping — it is suppressive, not curative.[2]

Safety80

Decades of cardiovascular safety data; mostly constipation, with dose-dependent bradycardia/AV block needing monitoring.[5]

Stage breadth30

Studied only at new-onset (stage 3); no evidence it prevents or delays disease in earlier stages 1–2.[1]

Access & cost90

Generic, inexpensive, oral, and globally available — though used off-label for this purpose, with no regulatory approval in T1D.[3]

Editor’s take

Not a blockbuster, and the honest headline from 2025 is that its biggest adult trial missed significance. But a cheap, safe, generic pill that demonstrably protects residual insulin production in newly diagnosed children is exactly the kind of low-risk, universally accessible lever worth taking seriously — most likely as a partner to immune therapies rather than a stand-alone fix.

The full picture

Verapamil is an old, inexpensive blood-pressure and heart-rhythm pill that turned out to do something unexpected in T1D: started around the time of diagnosis, it helps the surviving insulin-producing cells last longer, preserving more of the body's own insulin. It does not prevent or delay the disease — it tries to protect what remains at the moment of new-onset (stage 3) diagnosis.

Where verapamil fits: screening and staging

T1D develops in stages that can be detected years before symptoms. Stage 1 is two or more islet autoantibodies with normal glucose; stage 2 adds abnormal glucose; stage 3 is clinical diabetes needing insulin.1 Screening a blood sample for these autoantibodies identifies who is on this path — and finding people early sharply reduces the chance of presenting in diabetic ketoacidosis (DKA), a dangerous emergency: general-population screening programmes have cut DKA at diagnosis more than tenfold.2 Confirmed multiple-autoantibody positivity carries a very high lifetime risk of progression, and consensus guidance now recommends monitoring such individuals and offering trials or approved therapies.1 Verapamil, importantly, is not a screening-stage drug: its evidence is entirely at new-onset, after diagnosis. It complements early detection rather than acting on it.

The therapy: mechanism and effect

In the lab, verapamil lowers a stress protein (TXNIP) that drives insulin-producing-cell death, and it nudges human islets toward an anti-inflammatory, survival-favouring state.3 In the first human trial — 26 adults with recent-onset T1D given sustained-release verapamil titrated to 360 mg/day — stimulated C-peptide (the standard marker of the body's own insulin output) was significantly better preserved than placebo at both 3 and 12 months, with a between-group difference of about 0.28 nmol/L at 12 months.4 A larger follow-up showed the benefit persisted for at least two years with continued daily use, alongside lower insulin needs — but the effect was lost when people stopped, so it suppresses rather than cures.3

The strongest evidence is in children. The CLVer trial (NCT04233034, 88 newly diagnosed 7–17-year-olds) found verapamil partially preserved C-peptide at 52 weeks — roughly 30% higher than placebo (between-group difference 0.14 pmol/mL, P=0.04) — with 95% of the verapamil group versus 71% on placebo still making meaningful insulin.5

Safety is reassuring given decades of cardiovascular use: the main issue is constipation, with dose-dependent slowing of the heart (bradycardia, first-degree AV block) that needs an occasional ECG check.6 No approval exists for T1D, so it is used off-label; the drug itself is generic, oral, and available almost everywhere.4

What's coming

The honest 2025 headline is mixed. Ver-A-T1D — the largest adult trial (136 adults, 21 sites across six European countries, 360 mg/day) — narrowly missed statistical significance for its primary C-peptide endpoint, showing only a non-significant trend; investigators believe the placebo group declined less than expected, leaving the trial underpowered.6 Verapamil was again safe (first-degree AV block ~22%, bradycardia ~16%, both manageable).6 The takeaway from the field is that verapamil's effect is real but small, and its future most likely lies combined with immune-modulating disease-modifying therapies rather than alone — with longer follow-up and combination trials now the priority.6

References

  1. Phillip M, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia (2024). https://doi.org/10.1007/s00125-024-06205-5 ↩ ↩2

  2. Chiarelli F, Rewers M, Phillip M. Screening of Islet Autoantibodies for Children in the General Population: A Position Statement Endorsed by ESPE. Hormone Research in Paediatrics (2022). https://doi.org/10.1159/000525824 ↩

  3. Xu G, et al. Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes. Nature Communications (2022). https://doi.org/10.1038/s41467-022-28826-3 ↩ ↩2

  4. Ovalle F, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes (NCT02372253). Nature Medicine (2018). https://pmc.ncbi.nlm.nih.gov/articles/PMC6092963/ ↩ ↩2

  5. Forlenza GP, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes (CLVer; NCT04233034). JAMA (2023). https://doi.org/10.1001/jama.2023.2064 ↩

  6. Wych J, et al. Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed T1D (Ver-A-T1D protocol; NCT04545151). BMJ Open (2024). https://doi.org/10.1136/bmjopen-2024-091597 ; Ver-A-T1D results reported at EASD 2025. EurekAlert (2025). https://www.eurekalert.org/news-releases/1098672 ↩ ↩2 ↩3 ↩4

What's next for this

  • →Future use most likely combined with immune-modulating disease-modifying therapies rather than alone; longer follow-up and combination trials now the priority (after Ver-A-T1D narrowly missed its primary endpoint at EASD 2025)

Sources

  1. [1]Verapamil and beta cell function in adults with recent-onset type 1 diabetes (NCT02372253) · peer-reviewed · 2018-07-09
  2. [2]Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes · peer-reviewed · 2022-03-03
  3. [3]Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes (CLVer; NCT04233034) · peer-reviewed · 2023-03-28
  4. [4]Ver-A-T1D: protocol for a randomised, double-blind, placebo-controlled trial of verapamil in adults with newly diagnosed T1D (NCT04545151) · peer-reviewed · 2024-11-28
  5. [5]Study reports potential effects of verapamil in slowing progression of type 1 diabetes (Ver-A-T1D results, EASD 2025) · news · 2025-09-18
  6. [6]Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes · peer-reviewed · 2024-09-01
  7. [7]Screening of Islet Autoantibodies for Children in the General Population: A Position Statement Endorsed by ESPE · peer-reviewed · 2022-07-01